WO2015182470A1 - 腸管における物質取り込み促進剤 - Google Patents
腸管における物質取り込み促進剤 Download PDFInfo
- Publication number
- WO2015182470A1 WO2015182470A1 PCT/JP2015/064573 JP2015064573W WO2015182470A1 WO 2015182470 A1 WO2015182470 A1 WO 2015182470A1 JP 2015064573 W JP2015064573 W JP 2015064573W WO 2015182470 A1 WO2015182470 A1 WO 2015182470A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- val
- thr
- ala
- ser
- asn
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 47
- 239000000126 substance Substances 0.000 title claims abstract description 47
- 230000001737 promoting effect Effects 0.000 title abstract description 7
- 238000010348 incorporation Methods 0.000 title abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 146
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 76
- 241000894006 Bacteria Species 0.000 claims abstract description 74
- 239000004310 lactic acid Substances 0.000 claims abstract description 73
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 73
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 52
- 101710099182 S-layer protein Proteins 0.000 claims abstract description 41
- 101710168515 Cell surface glycoprotein Proteins 0.000 claims abstract description 40
- 241000186660 Lactobacillus Species 0.000 claims abstract description 32
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000002344 surface layer Substances 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 7
- 230000027455 binding Effects 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 101150027978 UMOD gene Proteins 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 20
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 19
- 102000018697 Membrane Proteins Human genes 0.000 claims description 17
- 108010052285 Membrane Proteins Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 16
- 108010027007 Uromodulin Proteins 0.000 claims description 12
- 102000018614 Uromodulin Human genes 0.000 claims description 12
- 239000013076 target substance Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 10
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 10
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000012041 food component Nutrition 0.000 claims description 6
- 239000005417 food ingredient Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 66
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 53
- 238000009739 binding Methods 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 15
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000013566 allergen Substances 0.000 description 11
- 210000001986 peyer's patch Anatomy 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 241000186606 Lactobacillus gasseri Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 241000509544 Lactobacillus gallinarum Species 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- -1 3-dimetylaminopropyl Chemical group 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 3
- 206010065764 Mucosal infection Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000008944 intestinal immunity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100048823 Mus musculus Umod gene Proteins 0.000 description 2
- 102000012064 NLR Proteins Human genes 0.000 description 2
- 108091005686 NOD-like receptors Proteins 0.000 description 2
- 241000202223 Oenococcus Species 0.000 description 2
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 239000013573 pollen allergen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710198693 Invasin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 241000022584 Lactobacillus amylovorus GRL1118 Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000039126 Lactobacillus helveticus CIRM-BIA 953 Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194038 Lactococcus plantarum Species 0.000 description 1
- 241000194037 Lactococcus raffinolactis Species 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000192134 Oenococcus oeni Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001092473 Quillaja Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 101710184697 S-layer protein A Proteins 0.000 description 1
- 108010082913 S-layer proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710183296 Surface layer protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000185 follicular epithelial cell Anatomy 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
Definitions
- the present invention relates to a substance uptake promoter in the intestinal tract, which contains a surface protein derived from lactic acid bacteria.
- the immune system exists as a defense system against the entry of foreign objects from the outside world.
- the intestinal tract immune system is the largest immune system, and is composed of 60% immune cells and antibodies of the entire immune system.
- Intestinal tract includes Peyer's patch (PP), lamina intestinal (Lamina Propria, LP), lamina basement lymphocytes (LaminapriPropria Lymphocytes, LPL), intestinal interepithelial cell lymphocytes (Intraepithelial Lymphocytes, IEL), intestinal tract Intestinal lymphoid tissue (gut-associated lymphoid tissue, GALT) composed of epithelial cells (Intestinal Epithelial Cell, IEC), crypt patches (Cryptopatch, CP), etc.
- M cells Macrofold cells
- follicular epithelial cells Follicle Epithelium, FAE
- pathogenic microorganisms such as dendritic cells
- the subsequent immune response is induced by delivering the antigen to various immunocompetent cells. Therefore, it is expected to efficiently act on immune cells by targeting M cells that are the gate of antigen uptake.
- Non-patent documents 1 to 3 Non-patent documents 1 to 3
- ingredients derived from materials such as pathogens that have no food experience remain uneasy about safety and are inappropriate for incorporation into the body. Therefore, a delivery system targeting M cells using ingredients derived from highly safe ingredients with abundant dietary experience is desired.
- Lactic acid bacteria are microbial cells (probiotics) that have the functions of adjusting the intestinal environment and acting on the intestinal tract immune system, and are used as functional components of foods that are ingested daily such as lactic acid bacteria beverages and yogurt.
- Probiotic lactic acid bacteria are also taken into the intestinal tract by M cells on Peyer's patches, and Toll-like receptors (TLRs) and Nod-like receptors are present in dendritic cells below M cells (in Peyer's patches) By acting on (NLR), it is speculated that various immune responses such as T cell activation, intestinal epithelial cell proliferation, IgA production promotion and inflammation suppression occur. Accordingly, establishment of an efficient means for taking up the intestinal tract is essential even in the use of probiotic lactic acid bacteria.
- an object of the present invention is to provide a means by which a substance useful for intestinal immunity induction such as lactic acid bacteria can be efficiently taken into the intestinal tract.
- the present inventors have found that the surface protein (SlpA protein) of Lactobacillus acidophilus L-92 strain is expressed in uromodulin protein (Umodlin protein) It was found to be involved in the binding of the lactic acid bacterial strain to) and promotion of uptake from M cells.
- uromodulin protein Umodlin protein
- the present invention includes the following inventions.
- a surface protein of a lactobacillus belonging to the genus Lactobacillus comprising at least one peptide motif consisting of an amino acid sequence represented by the following formulas (I) to (VI) and having binding activity to uromodulin (Umod) protein, A substance uptake promoter in the intestinal tract containing the fragment.
- X1 represents Val or Ile
- the surface protein may be Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus crispatus, Lactobacillus amylovorus, Lactobacillus amylovorus, or Lactobacillus amylovorus
- the complex according to (6), wherein the intestinal uptake target substance is a food ingredient.
- the complex according to (7), wherein the food ingredient is a lactic acid bacterium.
- the complex according to (6), wherein the intestinal uptake target substance is a pharmaceutical ingredient.
- the complex according to (9), wherein the pharmaceutical ingredient is a mucosal vaccine antigen.
- a composition comprising the complex according to any one of (6) to (10).
- X1 represents Val or Ile
- the surface protein (S-layer protein) derived from lactic acid bacteria which is an active ingredient of the substance uptake promoter in the intestinal tract of the present invention has an activity of binding to intestinal M cells and an action of promoting uptake of substances from intestinal M cells. Therefore, the substance uptake promoter in the intestinal tract of the present invention can increase the amount of intestinal uptake of useful lactic acid bacteria, mucosal vaccine antigens, etc., and as a result, effectively and reliably act on intestinal immunity, thereby suppressing allergic symptoms. And mucosal infections such as influenza can be protected. Moreover, since the substance uptake
- FIG. 1 shows the results of immunostaining of the test lactic acid strains (L-92 strain, CP23 strain, LiCl-L92 strain) (SlpA in which the white portion is stained).
- FIG. 1 shows the results of immunostaining of the test lactic acid strains (L-92 strain, CP23 strain, LiCl-L92 strain) (SlpA in which the white portion is stained).
- FIG. 6 shows the results of multiple alignment analysis of S-layer proteins of L. acidophilus, L. helveticus, and L. gasseri (motifs 1 to 6). : Lactobacillus acidophilus (L. acidophilus) and L. helveticus (L. helveticus) with high Umod binding are common, and conversely Lactobacillus gaseri (L. gasseri) with low Umod binding Not a peptide motif).
- FIG. 7 shows structural formulas (I) to (I) of a peptide motif common to the surface protein (L-protein) of Lactobacillus genus Lactobacillus having binding activity to uromodulin (Umod) protein determined by multiple alignment analysis.
- FIG. 8 shows a portion corresponding to the amino acid sequence of the peptide motif common to the surface protein (L-protein) of lactic acid bacteria belonging to the genus Lactobacillus having binding activity to uromodulin (Umod) protein. acidophilus), Lactobacillus helveticus (L. helveticus), Lactobacillus crispatus (L. crispatus), Lactobacillus amylovorus (L.
- amylovorus showing the amino acid sequence of Lactobacillus galinalum (L. gallinarum) (formula ( The number above the amino acid sequence of I) to (VI) is 1: amino acid common to 5 species of L. acidophilus, L. helveticus, L. crispatus, L. amylovorus, L. gallinarum, the number is 2: L Amino acid common to 3 bacterial species of .acidophilus, L.helveticus and L.crispatus, the number 3: amino acid common to 2 bacterial species of L. acidophilus and L.helveticus).
- Substance uptake promoter in intestinal tract contains at least one peptide motif consisting of amino acid sequences represented by the following formulas (I) to (VI), and against uromodulin (Umod) protein.
- a surface protein of lactic acid bacteria belonging to the genus Lactobacillus having a binding activity hereinafter referred to as “S-layer protein” or a fragment thereof.
- Formula (II): Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu in formula (II)
- X2 represents Asn or Ser
- X3 represents Thr or Ser
- X4 represents Thr or Ser
- the peptide motif contained in S-layer protein may have a mutation as long as it has binding activity to uromodulin (Umod) protein.
- Umod uromodulin
- amino acid substitution is preferably a conservative amino acid substitution, and the conservative amino acid substitution means a substitution between amino acids having similar properties such as structural, electrical, polar or hydrophobic properties. Such properties can be classified by, for example, similarity of amino acid side chains.
- amino acids having basic side chains lysine, arginine, histidine
- amino acids having acidic side chains amino acids having acidic side chains (aspartic acid, glutamic acid)
- amino acids having aliphatic side chains alanine, valine, leucine, isoleucine
- hydroxyl-containing side examples include amino acids having a chain (serine, threonine, tyrosine) and amino acids having an amide-containing side chain (asparagine, glutamine).
- S-layer protein used in the present invention examples include Lactobacillus us acidophilus, Lactobacillus helveticus, Lactobacillus crispatus, Lactobacillus cribuspatus, Lactobacillus lactovorus, -S-layer protein derived from Lactobacillus gallinarum is preferred.
- S-layer protein AA (hereinafter referred to as “SlpA protein”) present on the surface of Lactobacillus acidophilus L-92 strain is more preferable.
- the SlpA protein is a protein with a molecular weight of 43.6 kDa and an isoelectric point of 10.4, and has been known to have functions such as defense, cell character maintenance, molecular and ion adsorption and adhesion (FEMS Microbiol. Rev. 29 : 511-529).
- the present invention relates to a uromodulin (Umod) protein (hereinafter simply referred to as “a protein expressed in M cells existing in the epithelial cell layer of the small intestine Peyer's patch), which is a function of the SlpA protein that has not been known so far.
- Umod (which may be referred to as“ Umod ”) and substance uptake promotion activity from M cells.
- NCFM Lactobacillus acidophilus
- the SlpA protein is a protein consisting of the amino acid sequence shown in SEQ ID NO: 7, but may be a mutant protein as long as it has a binding activity to Umod and an activity of promoting substance uptake from M cells. It may be a protein (partial peptide) having a partial sequence of an amino acid sequence.
- mutant protein examples include a protein consisting of an amino acid sequence in which one to several amino acids are deleted, substituted, or added in the amino acid sequence shown in SEQ ID NO: 7.
- range of “1 to several” refers to a number that can be deleted, substituted, or added by a known mutant protein production method such as site-directed mutagenesis, as long as the activity is maintained. The number is not limited, but 1 to 30, preferably 1 to 20, more preferably 1 to 10, and most preferably 1 to 5.
- examples of the amino acid substitution include the conservative amino acid substitution described above.
- the mutant protein may be a protein comprising an amino acid sequence having 90% or more identity to the amino acid sequence shown in SEQ ID NO: 7.
- identity preferably means 95% or more, more preferably 97% or more, and most preferably 98% or more sequence identity.
- identity of amino acid sequences can be determined by FASTA search or BLAST search.
- mutation here means a mutation artificially introduced mainly by a known mutant protein production method, but may be a similar naturally occurring mutation.
- the SlpA protein used in the present invention may be prepared by a chemical synthesis method based on the amino acid sequence shown in SEQ ID NO: 7, or may be prepared by a gene recombination technique.
- a genetic recombination technique for example, an expression vector containing a gene encoding the amino acid sequence shown in SEQ ID NO: 7 is prepared, and an appropriate host cell is transformed with this expression vector to obtain a transformant.
- the transformant can be cultured, and the target protein can be mass-produced from the culture.
- An expression vector can be prepared and introduced into a host cell according to a known method.
- Either prokaryotic or eukaryotic cells can be used as host cells.
- Examples of commonly used prokaryotic host cells include Escherichia coli and Bacillus subtilis.
- Examples of eukaryotic cells include yeast cells.
- An expression vector can be introduced into a host cell by a known method, and examples thereof include a calcium phosphate method, a liposome method, an electroporation method, and a particle gun method.
- chromatographic methods such as ion exchange chromatography, affinity chromatography, high performance liquid chromatography, adsorption chromatography, gel filtration chromatography, etc., and salting out, ultrafiltration, gel filtration, dialysis, urea, etc.
- chromatographic methods such as ion exchange chromatography, affinity chromatography, high performance liquid chromatography, adsorption chromatography, gel filtration chromatography, etc., and salting out, ultrafiltration, gel filtration, dialysis, urea, etc.
- examples include a combination of a treatment with a denaturing agent or a surfactant, centrifugation, ultrasonic treatment, enzyme digestion and the like.
- the surface protein fragment of lactic acid bacteria belonging to the genus Lactobacillus having binding activity to the uromodulin (Umod) protein of the present invention is a fragment of the “S-layer protein” defined above, which is the uromodulin (Umod) protein.
- the length is not limited as long as it has binding activity. For example, at least 20 amino acids, preferably 50 or more, and more preferably 100 or more amino acids constituting the S-layer protein. Examples include fragments having a sequence.
- the substance uptake promoter in intestinal tract of the present invention forms a complex with a substance targeted for intestinal uptake (hereinafter referred to as “target substance”).
- target substance a substance targeted for intestinal uptake
- the target substance can be efficiently taken into the intestinal tract.
- a target substance what is necessary is just a substance which shows activity in the living body, when taken in from an intestinal tract, for example, a food ingredient, a pharmaceutical ingredient, etc. are mentioned.
- food ingredients and pharmaceutical ingredients having an intestinal immunity induction effect are preferable, and examples thereof include lactic acid bacteria and mucosal vaccine antigens.
- the lactic acid bacteria may be live or dead. In the case of dead bacteria, it may be crushed.
- the disruption of the microbial cells can be performed by, for example, physical disruption, enzyme dissolution treatment, and the like using methods and equipment known in the art. Physical crushing may be carried out either wet (treated in the state of a cell suspension) or dry (treated in the state of a cell powder), using a homogenizer, ball mill, bead mill, dyno mill, planetary mill, etc. It can be carried out by stirring, by pressure using a jet mill, a French press, a cell crusher or the like, or by filter filtration.
- an enzyme such as lysozyme can be used to destroy the cell walls of the cells.
- the substance uptake promoter in the intestine may be in a state of being covalently bonded or non-covalently bonded to the target substance, and the binding means is not particularly limited.
- the target substance when the target substance is a lactic acid bacterium that does not have S-layer protein on its surface, bind the substance uptake promoter in the intestinal tract directly or through an appropriate cross-linking agent (linker) to the surface of the lactic acid bacterium.
- an appropriate cross-linking agent linker
- a complex can be formed.
- a method for forming a complex for example, targeting amino groups, carboxyl groups, sulfhydryl groups, preferably amino groups of proteins (such as sugar chain receptor proteins) present on the surface layer of lactic acid bacteria to be taken up, And a method using a protein cross-linking agent having a reactive functional group capable of binding to the above group.
- the S-layer protein can be added to the surface of lactic acid bacteria by linking an anchor motif (eg, CWBD motif, LysM motif, GW motif) involved in noncovalent binding to the cell walls of lactic acid bacteria and S-layer protein.
- an anchor motif eg, CWBD motif, LysM motif, GW motif
- anchor expression for example LPXTG motif
- a method of peptide-binding the protein and S-layer protein using a protein cross-linking enzyme transglutaminase
- a complex can be formed by binding the substance uptake promoter in the intestinal tract to the mucosal vaccine antigen directly or via an appropriate carrier.
- a method of creating a fusion protein of mucosal vaccine antigen to be taken up and S-layer protein a method of introducing a reactive group into a carrier encapsulating mucosal vaccine antigen, and binding S-layer protein can be used.
- the carrier include liposomes, microspheres or nanospheres, biodegradable carriers such as PLGA (polylactic acid / glycolic acid), mucoadhesive carriers composed of hyaluronic acid, chitin and the like.
- a fusion protein of S-layer protein and mucosal vaccine antigen can be produced by a known gene recombination technique.
- a fusion gene in which a gene encoding S-layer protein and a gene encoding mucosal vaccine antigen protein are artificially linked is prepared, and the fusion gene is inserted downstream of the promoter of the expression vector. It can be obtained by introducing it into a cell and expressing it.
- the binding order of S-layer protein and mucosal vaccine antigen is not limited.
- the base sequence information of the gene encoding the mucosal vaccine antigen protein can be obtained from a known database (GenBank, etc.).
- base sequence information can be obtained by cloning a target gene using a known method and performing base sequence analysis.
- the lipid composition and size of the liposome and the S-layer protein binding method are not particularly limited.
- the lipid composition and size of the liposome and the S-layer protein binding method are not particularly limited.
- lipids having a lipid terminal carboxyl group or maleimide group for S-layer protein binding are used.
- Encapsulation of the antigen in the liposome can be performed by a known freeze-thaw method, reverse phase evaporation method, hydration method, or the like.
- S-layer protein is added to the prepared antigen-encapsulated liposome, and a conjugate of liposome and S-layer protein can be prepared by peptide condensation reaction or SH group reaction system.
- Composition comprising a complex of a substance uptake promoter in the intestinal tract and a substance to be taken up by the intestine
- the above complex can be blended with a suitable additive in a composition such as a food, drink, pharmaceutical or animal feed.
- the drug includes not only human drugs but also veterinary drugs.
- Animal feed includes feed for livestock (pigs, cattle, etc.) and pet food for pets (dogs, cats, etc.).
- a complex whose intestinal uptake target substance is a lactic acid bacterium can be incorporated into food and drink.
- the food / beverage product is used to mean including a health food, a functional food, a dietary supplement, or a food for specified health use.
- dairy products such as yogurt, cheese, beverages containing lactic acid bacteria, and pickles are optimal.
- the form of the food and drink may be any form suitable for food, for example, solid, liquid, granular, granular, powdery, capsule (hard capsule, soft capsule), cream, or paste.
- shapes suitable for health foods and functional foods include tablet shapes, capsule shapes, granule shapes, and powder shapes.
- a tablet-like health food is produced by compressing a formulation containing a lactic acid bacterium combined with a substance uptake promoter in the intestinal tract according to the present invention into a certain shape or water or alcohol.
- the kneaded material moistened with a solvent such as the above can be formed into a fixed shape, or poured into a fixed mold and molded.
- the complex whose intestinal uptake target substance is a mucosal vaccine antigen can be blended in a pharmaceutical, particularly a mucosal vaccine preparation.
- a pharmaceutical particularly a mucosal vaccine preparation.
- it may be formulated together with an adjuvant for enhancing the immune response.
- adjuvants include aluminum hydroxide, BCG, aluminum phosphate, keyhole limpet hemocyanin, dinitrophenol, dextran, and TLR ligands (eg, lipopolysaccharide (LPS), CpG).
- the mucosal vaccine antigen is not particularly limited as long as it can induce a mucosal immune response, but is typically an antigen derived from a pathogen of mucosal infection.
- the pathogen of the mucosal infection may be a virus or a bacterium.
- viruses include influenza virus, human immunodeficiency virus (HIV), varicella virus, measles virus, rubella virus, poliovirus, rotavirus, adenovirus, herpes virus, severe acute respiratory infection syndrome (SARS) virus, etc. Although not limited to these.
- bacteria examples include, but are not limited to, Bordetella pertussis, Neisseria meningitidis, influenza b type bacteria, pneumococci, and tuberculosis bacteria.
- pathogen-derived antigens may be derived from natural products, or may be artificially prepared by a technique such as gene recombination.
- the vaccine antigens include allergens used for desensitization therapy.
- An allergen vaccine is a type 1 helper T cell (Th1) that blocks allergen-specific IgE in vivo by producing IgG antibodies against the allergen by administering the allergen to the body. Is a vaccine to increase type 2 cells and decrease type 2 helper T cells (Th2 cells) involved in allergic symptoms. Allergic symptoms can be suppressed by desensitization.
- allergens are not particularly limited, but food allergens (casein, lactalbumin, lactoglobulin, ovomucoid, ovalbumin, conalbumin etc.), house dust allergens (eg mite allergen etc.), pollen allergens (cedar pollen allergen, ragweed) Allergens such as allergens and hemlock allergens) and animal hairs.
- food allergens casein, lactalbumin, lactoglobulin, ovomucoid, ovalbumin, conalbumin etc.
- house dust allergens eg mite allergen etc.
- pollen allergens cedar pollen allergen, ragweed
- Allergens such as allergens and hemlock allergens
- the present invention also relates to the expression level of S-layer protein in the surface layer of lactic acid bacteria of the test lactic acid bacteria based on the binding activity of SlpA protein to Umod and the substance uptake promoting activity from M cells And a method for screening lactic acid bacteria having a high ability to enter the intestinal tract.
- the S-layer protein may be used as it is, but a protein labeled with any labeling substance can also be used.
- labeling substances include fluorescent substances, radioisotopes (for example, 125 I, 3 H, 14 C, 35 S, etc.), chemiluminescent substances, biotin, marker proteins, peptide tags, and the like.
- the marker protein include an antibody Fc region, alkaline phosphatase, HRP (Horse radish peroxidase), and the like.
- the peptide tag include FLAG, 6 ⁇ His or 10 ⁇ His consisting of 6 or 10 His (histidine) residues, a fragment of influenza agglutinin (HA), and the like.
- intestinal transit ability refers to the ability to adhere to intestinal M cells, migrate into M cells, reach the Peyer's patch via the basement membrane in M cells.
- the expression level of S-layer protein in the surface layer of the test lactic acid bacterium may be measured by comparison with a standard sample, but the absolute amount of S-layer protein is not necessarily absolute. It is not necessary to measure the amount, and it is sufficient for evaluation if the relative relationship with S-layer protein in the surface layer of lactic acid bacteria as a control can be clarified.
- the measurement of the expression level of S-layer protein can be performed according to a known protein expression analysis method.
- a typical example is an immunoassay using an antibody against S-layer protein.
- the immunological measurement method is not particularly limited, and conventionally known methods such as enzyme immunoassay (EIA method), latex agglutination method, immunochromatography method, Western blot method, radioimmunoassay method (RIA method), Fluorescence immunoassay (FIA method), luminescence immunoassay, spin immunoassay, turbidimetric method for measuring turbidity associated with antigen-antibody complex formation, potential change due to antigen binding using antibody solid phase membrane electrode An enzyme sensor electrode method, an immunoelectrophoresis method, and the like that detect the above can be employed.
- EIA method or Western blot method is preferable.
- the EIA method includes a competitive enzyme immunoassay method, a sandwich enzyme-linked immunosorbent solid phase assay method (sandwich ELISA method), and
- the antibody against S-layer protein used in the above measurement can be obtained by a method well known to those skilled in the art.
- the antibody may be a polyclonal antibody or a monoclonal antibody. Further, the antibody may be an active fragment of an antibody. Active fragments include F (ab ′) 2, Fab ′, Fab, Fv and the like.
- a polyclonal antibody against S-layer protein blood is collected from a mammal (for example, rabbit, rat, mouse, etc.) sensitized with an antigen, and serum is separated from the blood by a known method.
- serum containing the polyclonal antibody can be used as the polyclonal antibody.
- antibody-producing cells spleen cells, lymph node cells, etc.
- the thus obtained hybridoma can be cloned, and the antibody can be recovered from the culture to obtain a monoclonal antibody.
- these antibodies may be labeled appropriately.
- the labeling substance the aforementioned enzyme, radioisotope, or fluorescent dye can be used.
- a substance that specifically binds to the antibody such as protein A or protein G, can be labeled and detected indirectly without labeling the antibody.
- the lactic acid bacterium to be tested is any lactic acid strain belonging to the genus Lactobacillus, Lactococcus, Bifidobacterium, Leuconostoc, Streptococcus, Enterococcus, Pediococcus, Weisella, Oenococcus, etc. Also good.
- Lactobacillus belonging to the genus Lactobacillus includes Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus delbrucchi, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus kefir, Lactobacillus Paracasei, Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus amylovorus, Lactobacillus crisptus, Lactobacillus gallinalum Is mentioned.
- Lactococcus lactis examples include Lactococcus lactis, Lactococcus plantarum, Lactococcus raffinolactis and the like.
- Lactic acid bacteria belonging to the genus Bifidobacterium include Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Examples include Bifidobacterium animalis, Bifidobacterium adrecentis, Bifidobacterium catenatum, Bifidobacterium pseudocatenatum, and the like.
- Examples of lactic acid bacteria belonging to the genus Leuconostoc include Leuconostoc lactis and Leuconostoc mesenteroides.
- Examples of lactic acid bacteria belonging to the genus Streptococcus include Streptococcus thermophilus and Streptococcus lactis.
- Examples of lactic acid bacteria belonging to the genus Enterococcus include Enterococcus faecalis, Enterococcus dulans, Enterococcus faecium and the like.
- Examples of lactic acid bacteria belonging to the genus Pediococcus include Pediococcus pentosaceus.
- lactic acid bacteria belonging to the genus Weicella examples include Weicera tivaria, Weicera confuser, Weicera halotolerance and the like.
- lactic acid bacteria belonging to the genus Oenococcus examples include Oenococcus oeni.
- Example 1 SlpA quantification of lactic acid strain (1) Preparation of lactic acid strain Lactobacillus acidophilus L-92 strain and Lactobacillus acidophilus CP23 strain were used for the experiment. Each strain was incubated at 37 ° C. for 20 hours in an MRS medium (Difco), washed with PBS three times, and suspended in PBS.
- MRS medium Difco
- LiCl treatment of the L-92 strain was performed by washing the L-92 strain twice with PBS, removing the supernatant, and incubating at room temperature and standing for a certain period of time in a 5 M LiCl (Wako) solution. Was done. After incubation, the cells were again washed twice with PBS and then resuspended in PBS.
- the L-92 strain had a cell surface covered with SlpA, whereas the CP23 strain showed less SlpA localized on the surface. Furthermore, it was shown that the SlpA on the surface of the L-92 strain treated with LiCl was almost removed (FIG. 1).
- Example 2 Evaluation of Umod binding property of lactic acid strain (1) Preparation of Lactic Acid Bacteria L-92 strain, CP23 strain and LCl-treated L-92 strain prepared in the same manner as in Example 1 were used for the experiment.
- the anti-SlpA antibody treatment of the L-92 strain was performed by suspending the L-92 strain in a PBS solution in which the anti-SlpA antibody was dissolved to a final concentration of 140 ⁇ g / ml, and gently shaking overnight at 4 ° C. went.
- Forward primer 5′-CGCAGATCTACCATGGGGATCCCTTTGACC-3 ′ (SEQ ID NO: 10) and Reverse primer: 5′-CGCGTCGACCTTGGACACTGAGGCCTGG-3 ′ (SEQ ID NO: 11) as primers for amplifying the mUmod (mouse Umod) sequence (SEQ ID NO: 9) And cloned into pcDNA3 vector (invitrogen) inserted with Fc domain using restriction enzymes BglII and SalI.
- the vector obtained by cloning Fc-mUmod was introduced into human fetal kidney cell-derived HEK293T cells and cultured for 7-10 days.
- the Fc-mUmod protein secreted in the supernatant was recovered and purified using HiTrap® protein® AHP® affinity column (GE® Healthcare).
- DNA was extracted from the cells bound to the plate using NucleoSpin TM Tissue (Takara). The method followed the attached protocol. Using the extracted DNA as a template, universal primers (F: 5'-AACTGGAGGAAGGTGGGGAT-3 '(SEQ ID NO: 12), R: 5'-AGGAGGTGATCCAACCGCA-3' (SEQ ID NO: 13)) targeting the 16S rRNA gene Real-time PCR was performed to quantify the number of bacteria bound to Fc-mUmod and hIgG. The method followed the protocol attached to SYBR TM Premix Ex Taq TM II (Tli RNaseH Plus) (Takara).
- SYBR TM Premix Ex Taq TM II Tli RNaseH Plus
- the value obtained by subtracting the number of bacteria bound to hIgG from the number of bacteria bound to Fc-mUmod was defined as the number of Umod bindings.
- the number of Umod bindings of each strain was expressed as a ratio relative to the binding number of the L-92 strain as 100%. The results are shown in FIGS.
- Example 3 Evaluation of uptake amount of Lactobacillus strains into M cells (1) Preparation of Lactic Acid Bacteria L-92 strain, CP23 strain and LCl-treated L-92 strain prepared in the same manner as in Example 1 were used for the experiment.
- Rat anti-mouse GP2 IgG2a (clone 2F11-C3) (1.0 mg / ml) is incubated in a primary antibody solution diluted to 100-fold in blocking solution, washed well with washing solution, and then Alexa Fluor TM 488 Goat anti-rat IgG (H + L) (Invitrogen) (2.0 mg / ml) was incubated in a secondary antibody solution diluted to 200-fold in a blocking solution. Tissues that had been thoroughly washed with PBS were mounted in whole and used for observation.
- the amount of each strain incorporated into the M cells was expressed as a ratio relative to the amount of L-92 strain incorporated as 100%.
- the results are shown in FIG.
- Example 4 Evaluation of the amount of SlpA binding carrier incorporated into M cells (1) Isolation and purification of SlpA Lactobacillus acidophilus L-92 strain was incubated in 5M LiCl for 30 minutes to extract SlpA. After centrifuging to remove the bacterial cells, dialysis was performed with a PBS solution using a dialysis tube (20/32 mm, Nippon Medical Science) to obtain SlpA. It was confirmed by SDS-PAGE and CBB staining that a single band was obtained.
- Peyer's board incorporation amount Peyer's board was cut out and washed with 1xHBSS (GIBCO), and then a frozen block was prepared using OCTcompound (Sakura Fintek USA).
- a cryostat LEICA CM1850 was used to prepare a frozen section having a thickness of 5 mm, and the number of beads incorporated into the Peyer plate was observed and measured with a fluorescence microscope. Six to 12 sections per mouse were observed and the average was determined.
- Fig. 5 shows a comparison of the amount of fluorescent beads combined with SlpA and fluorescent beads combined with BSA into the Peyer plate. It was confirmed that the amount of uptake from M cells was promoted by binding SlpA.
- Example 5 Evaluation of Umod binding property of various lactic acid strains (1) Preparation of test lactic acid bacteria About 20 lactic acid bacteria belonging to the genus Lactobacillus were used in the experiment. In the same manner as in Example 1, each strain was incubated at 37 ° C. for 20 hours in an MRS medium (Difco), washed with PBS three times, and suspended in PBS.
- Table 1 shows the calculation results of the number of Umod bindings of the 14 lactic acid bacteria to be tested.
- the value obtained by subtracting the number of bacteria bound to hIgG from the number of bacteria bound to Fc-mUmod was defined as the number of Umod bindings.
- Example 6 Examination of the common sequence present in the amino acid sequence of S-layer protein on the surface of lactic acid bacteria Based on the results of Example 5, multiple alignment analysis of S-layer protein was performed using ClutalW (http: // clustalw. ddbj.nig.ac.jp/).
- Lactobacillus acidophilus gi
- Lactobacillus helveticus gi
- Lactobacillus gasseri gi
- Lactobacillus acidophilus and Lactobacillus helveticus with high Umod binding are commonly shared, and conversely, Lactobacillus gasseri with low Umod binding are not included in formulas (I) to (VI) (FIG. 7).
- Lactobacillus acidophilus is considered to be a related species of Lactobacillus acidophilus ( gi
- FIG. 8 shows amino acid sequences represented by the formulas (I) to (VI) and the corresponding portions of Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus crispatas, Lactobacillus amyloborus, Lactobacillus gallinalum.
- the amino acid sequence is shown (SEQ ID NOs: 14 to 43). Among these five species, it was found that formula (V) had the highest commonality and formula (VI) had the lowest commonality.
- the present invention can be used in the field of producing pharmaceuticals such as probiotic foods and drinks and mucosal vaccines.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
Abstract
Description
(1) 下記の式(I)~(VI)に示すアミノ酸配列からなるペプチドモチーフの少なくとも1種を含み、かつウロモジュリン(Umod)蛋白質に対して結合活性を有するラクトバチルス属の乳酸菌の表層蛋白質又はその断片を含有する、腸管における物質取り込み促進剤。
式(I):Asn-Thr-Asn-Thr-Asn-Ala-Lys-Tyr-Asp-Val-Asp-Val-Thr-Pro-Ser-Val-Ser-Ala-X1-Ala (式(I)中、X1はValまたはIleを表す)
式(II):Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu (式(II)中、X2はAsnまたはSerを表し、X3はThrまたはSerを表し、X4はThrまたはSerを表す)
式(III):Tyr-Thr-Val-Thr-Val-X5-Asp-Val-Ser-Phe-Asn-Phe-Gly-Ser-Glu-Asn-Ala- Gly-Lys (式(III)中、X5はAsnまたはProを表す)
式(IV):Val-Val-Ala-Ala-Ile-X6-Ser-Lys-Tyr-Phe-Ala-Ala-Gln-Tyr-Ala (式(IV)中、X6はAsnまたはThrを表す)
式(V):His-Thr-Phe-Thr-Val-Asn-Val-Lys-Ala-Thr-Ser-Asn-X7-Asn-X8-Lys-Ser-Ala Thr-Leu-Pro-Val (式(V)中、X7はThrまたはValを表し、X8はGlyまたはSerを表す)
式(VI):Val-Thr-Val-Pro-Asn-Val-Ala-Glu-Pro-Thr-Val-X9-Ser-Val-Ser-Lys (式(VI)中、X9はAlaまたはProを表す)
(2) 前記式(I)~(VI)で示されるアミノ酸配列において、1~10個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなるペプチドモチーフの少なくとも1種を含み、かつウロモジュリン(Umod)蛋白質に対して結合活性を有するラクトバチルス属の乳酸菌の表層蛋白質を含有する、(1)に記載腸管における物質取り込み促進剤。
(3) 前記表層蛋白質が、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)、ラクトバチルス・ヘルベティカス(Lactobacillus helveticus)、ラクトバチルス・クリスパタス(Lactobacillus crispatus)、ラクトバチルス・アミロボラス(Lactobacillus amylovorus)、またはラクトバチルス・ガリナルム(Lactobacillus gallinarum)由来のS-layer proteinである、(1)または(2)に記載の腸管における物質取り込み促進剤。
(4) 前記表層蛋白質がラクトバチルス・アシドフィルス由来のSlpA蛋白質である、(1)~(3)のいずれかに記載の腸管における物質取り込み促進剤。
(5) 前記ラクトバチルス・アシドフィルス由来のSlpA蛋白質が以下の(a)~(c)のいずれかの蛋白質である、(4)に記載の腸管における物質取り込み促進剤。
(a) 配列番号7に示すアミノ酸配列からなる蛋白質
(b) 配列番号7に示すアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる蛋白質
(c) 配列番号7に示すアミノ酸配列と90%以上の配列同一性を有する蛋白質
(6) (1)~(5)のいずれかに記載の腸管における物質取り込み促進剤と腸管取り込み対象物質との複合体。
(7) 前記腸管取り込み対象物質が食品成分である、(6)に記載の複合体。
(8) 前記食品成分が乳酸菌である、(7)に記載の複合体。
(9) 前記腸管取り込み対象物質が医薬品成分である、(6)に記載の複合体。
(10) 前記医薬品成分が粘膜ワクチン抗原である、(9)に記載の複合体。
(11) (6)~(10)のいずれかに記載の複合体を含む組成物。
(12) 飲食品、医薬品または動物用飼料である、(11)に記載の組成物。
(13) 被検乳酸菌の菌体表層における、下記式(I)~(VI)で示されるアミノ酸配列からなるペプチドモチーフの少なくとも1種を含む蛋白質の発現量を測定することを含む、腸管内移行能が高い乳酸菌のスクリーニング方法。
式(I):Asn-Thr-Asn-Thr-Asn-Ala-Lys-Tyr-Asp-Val-Asp-Val-Thr-Pro-Ser-Val-Ser-Ala-X1-Ala (式(I)中、X1はValまたはIleを表す)
式(II):Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu (式(II)中、X2はAsnまたはSerを表し、X3はThrまたはSerを表し、X4はThrまたはSerを表す)
式(III):Tyr-Thr-Val-Thr-Val-X5-Asp-Val-Ser-Phe-Asn-Phe-Gly-Ser-Glu-Asn-Ala- Gly-Lys (式(III)中、X5はAsnまたはProを表す)
式(IV):Val-Val-Ala-Ala-Ile-X6-Ser-Lys-Tyr-Phe-Ala-Ala-Gln-Tyr-Ala (式(IV)中、X6はAsnまたはThrを表す)
式(V):His-Thr-Phe-Thr-Val-Asn-Val-Lys-Ala-Thr-Ser-Asn-X7-Asn-X8-Lys-Ser-Ala Thr-Leu-Pro-Val (式(V)中、X7はThrまたはValを表し、X8はGlyまたはSerを表す)
式(VI):Val-Thr-Val-Pro-Asn-Val-Ala-Glu-Pro-Thr-Val-X9-Ser-Val-Ser-Lys (式(VI)中、X9はAlaまたはProを表す)
本発明の腸管における物質取り込み促進剤は、下記式(I)~(VI)で示されるアミノ酸配列からなるペプチドモチーフの少なくとも1種を含み、かつウロモジュリン(Umod)蛋白質に対して結合活性を有するラクトバチルス属の乳酸菌の表層蛋白質(以下、本表層蛋白質を「S-layer protein」と称する)又はその断片を含有する。
式(I):Asn-Thr-Asn-Thr-Asn-Ala-Lys-Tyr-Asp-Val-Asp-Val-Thr-Pro-Ser-Val-Ser-Ala-X1-Ala(式(I)中、X1はValまたはIleを表す) (配列番号1)
式(II):Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu(式(II)中、X2はAsnまたはSerを表し、X3はThrまたはSerを表し、X4はThrまたはSerを表す) (配列番号2)
式(III):Tyr-Thr-Val-Thr-Val-X5-Asp-Val-Ser-Phe-Asn-Phe-Gly-Ser-Glu-Asn-Ala- Gly-Lys (式(III)中、X5はAsnまたはProを表す) (配列番号3)
式(IV):Val-Val-Ala-Ala-Ile-X6-Ser-Lys-Tyr-Phe-Ala-Ala-Gln-Tyr-Ala (式(IV)中、X6はAsnまたはThrを表す) (配列番号4)
式(V):His-Thr-Phe-Thr-Val-Asn-Val-Lys-Ala-Thr-Ser-Asn-X7-Asn-X8-Lys-Ser-Ala Thr-Leu-Pro-Val (式(V)中、X7はThrまたはValを表し、X8はGlyまたはSerを表す) (配列番号5)
式(VI):Val-Thr-Val-Pro-Asn-Val-Ala-Glu-Pro-Thr-Val-X9-Ser-Val-Ser-Lys (式(VI)中、X9はAlaまたはProを表す) (配列番号6)
本発明の腸管における物質取り込み促進剤は、腸管取り込み対象物質(以下、「対象物質」という)との複合体を形成させることにより、該対象物質を腸管内に効率的に取り込ませることができる。対象物質としては、腸管から取り込まれた場合に生体内で活性を示す物質であればよく、例えば、食品成分や医薬品成分などが挙げられる。特に、腸管免疫誘導効果を有する食品成分や医薬品成分が好ましく、例えば、乳酸菌や粘膜ワクチン抗原などが挙げられる。
上記の複合体は、適当な添加物とともに飲食品、医薬品や動物用飼料などの組成物に配合することができる。ここで、医薬品には、ヒト用医薬品のみならず、動物用医薬品をも包含するものとする。また、動物用飼料には、家畜(ブタ、ウシ等)用の飼料、愛玩動物(犬、猫等)用のペットフードをも包含するものとする。
本発明はまた、SlpA蛋白質のUmodへの結合活性およびM細胞からの物質取り込み促進活性に基づき、被検乳酸菌の菌体表層におけるS-layer proteinの発現量を測定することを含む、腸管内移行能が高い乳酸菌のスクリーニング方法を提供する。
(1)乳酸菌株の調製
実験には、Lactobacillus acidophilus L-92株、Lactobacillus acidophilus CP23株を用いた。各菌株をMRS培地(Difco)にて37℃、20時間静置培養した後、PBSにて3回洗菌し、PBSに懸濁した。
菌体懸濁液10μlをスライドガラスに塗布し乾燥させた後、アルコールランプにて火炎固定した。Mouse anti-SlpA (clone 383)(1.4 mg/ml)をPBSにて100倍希釈し、スライドグラスに載せた。室温にて2~3時間反応させた後、PBSにてスライドグラスを3回洗浄した。さらに、Cy3-ストレプトアビジン(Cy3-conjugated Streptavidin、ImmunoResearch Labolatories, INC.、No.016-160-084)をPBSにて200倍希釈して、スライドグラスに載せた。室温にて2~3時間反応させた後、PBSにてスライドグラスを3回洗浄した。
(1)乳酸菌株の調製
実験には、実施例1と同様にして調製したL-92株、CP23株、LiCl処理したL-92株を用いた。L-92株の抗SlpA抗体処理は、抗SlpA抗体を終濃度140μg/mlとなるように溶解したPBS溶液にL-92株を懸濁し、4℃で一晩、穏やかに振とうすることによって行った。
L-92株、CP23株、LiCl処理したL-92株(LiCl-L92)、及び抗SlpA抗体処理したL-92株についてUmod結合性を調べた。
まず、ヒトIgG1のFcドメインにマウスUmod蛋白質(配列番号8の1-616位)をつなげて発現させた融合蛋白質(Fc-mUmod)を、Hase K. et al., Uptake through glycoprotein 2 of FimH1 bacteria by M cells initiates mucosal immune response, Nature 2009, 462:226-31の記載に従って作製した。mUmod(マウスUmod)配列(配列番号9)を増幅させるためのプライマーとしてForwardプライマー:5’-CGCAGATCTACCATGGGGATCCCTTTGACC-3’(配列番号10)およびReverse プライマー:5’-CGCGTCGACCTTGGACACTGAGGCCTGG-3’(配列番号11)を用い、制限酵素BglIIとSalIを用いてFcドメインを挿入したpcDNA3ベクター(invitrogen)にクローニングした。
(1)乳酸菌株の調製
実験には、実施例1と同様にして調製したL-92株、CP23株、LiCl処理したL-92株を用いた。
L-92株、CP23株、LiCl処理したL-92株は、Cy3 Mono-Reactive Dye Pack(GE Healthcare)によって蛍光標識し、109 cells/mlとなるようにPBSに懸濁した。手順はメーカーの推奨プロトコルに従った。C57BL/6Jマウスを数時間絶食させた後、イソフルラン麻酔下において開腹し、小腸パイエル板の両側を糸で縛り、菌体溶液を100μlずつ(108 cellsずつ)ループ部位に注入した。1時間インキュベートした後に頚椎脱臼にてマウスを安楽死させた。
パイエル板を切り出し、1 x HBSS(GIBCO)にて洗浄した後、BD Cytofix/CytopermTM(BD Bioscience)にて固定し、Perm/WashTM Buffer 10x(BD Bioscience)をmilliQ水で1x に希釈し、Saponin from Quillaja bark(SIGMA)を終濃度0.1%となるように添加した洗浄液にてよく洗い、洗浄液に0.2%となるようにBSAを懸濁させたブロッキング溶液でブロッキングを行った。
共焦点顕微鏡Leica SP2 AOBS Conforcal and Multiphoton(Leica)にて濾胞上皮領域を撮影し、Alexa 488により免疫染色されたM細胞と、Cy3標識された菌体が重なっている部分を、「M細胞に取り込まれている菌体」としてカウントした。Image J(http://rsb.info.nih.gov/ij/download.htmlよりダウンロード)を用いて、濾胞上皮部分の面積を測定し、面積あたりでM細胞に取り込まれている菌体量(Cy3+M cells/PP dome area (cells/mm2))を算出した。
(1)SlpAの単離精製
Lactobacillus acidophilus L-92株を5MのLiCl中で30分インキュベートし、SlpAを抽出した。遠心して菌体を除去した後、透析チューブ(20/32吋、日本メデカルサイエンス)を用いてPBS溶液にて透析し、SlpAを得た。SDS-PAGEおよびCBB染色により単一のバンドが得られたことを確認した。
2色の蛍光ビーズ(FluoSpheres(登録商標)calboxylate-modified microspheres 1.0 mm, orange / yellow-green(Invitrogen))に(1)で単離精製したSlpAまたはBSAを共有結合させた。EDAC[1-Ethyl-3-(3-dimetylaminopropyl) carbodimide, hydrochloride] (同仁化学研究所)を用い、手順はメーカーの推奨プロトコルに従った。
インキュベート時間を2時間とする以外は、実施例3に記載のとおり行った。
パイエル板を切り出し、1xHBSS(GIBCO)にて洗浄した後、O.C.T.compound(Sakura Fintek USA)を用いて凍結ブロックを作成した。クリオスタットLEICA CM1850を用いて5mm厚さの凍結切片を作成し、パイエル板内部に取り込まれているビーズの数を蛍光顕微鏡にて観察および測定した。1マウスあたり6~12切片を観察し、平均を求めた。
(1)被検乳酸菌の調製
実験には、ラクトバチルス属に属する乳酸菌約20株を用いた。各菌株は、実施例1と同様に、MRS培地(Difco)にて37℃、20時間静置培養した後、PBSにて3回洗菌し、PBSに懸濁した。
各菌株のUmod結合性の評価は、実施例2と同様に実施した。
実施例5の結果を踏まえ、S-layer proteinのマルチプルアライメント解析をClutalW(http://clustalw.ddbj.nig.ac.jp/)を用いて行った。具体的にはゲノム情報の利用が可能なラクトバチルス属に属する菌種の中で、実施例5において比較的にUmod結合性が高いことが確認されたラクトバチルス・アシドフィルス(gi|58336516|ref|YP_193101.1| S-layer protein [Lactobacillus acidophilus NCFM])、およびラクトバチルス・ヘルベティカス(gi|550820440|emb|CDI42266.1| Surface layer protein [Lactobacillus helveticus CIRM-BIA 953])が共通して保有し、逆にUmod結合性が低いことが確認されたラクトバチルス・ガセリ(gi|1619598|emb|CAA69725.1| aggregation promoting protein [Lactobacillus gasseri])が保有しない配列を特定した。
Claims (13)
- 下記の式(I)~(VI)に示すアミノ酸配列からなるペプチドモチーフの少なくとも1種を含み、かつウロモジュリン(Umod)蛋白質に対して結合活性を有するラクトバチルス属の乳酸菌の表層蛋白質又はその断片を含有する、腸管における物質取り込み促進剤。
式(I):Asn-Thr-Asn-Thr-Asn-Ala-Lys-Tyr-Asp-Val-Asp-Val-Thr-Pro-Ser-Val-Ser-Ala-X1-Ala (式(I)中、X1はValまたはIleを表す)
式(II):Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu (式(II)中、X2はAsnまたはSerを表し、X3はThrまたはSerを表し、X4はThrまたはSerを表す)
式(III):Tyr-Thr-Val-Thr-Val-X5-Asp-Val-Ser-Phe-Asn-Phe-Gly-Ser-Glu-Asn-Ala- Gly-Lys (式(III)中、X5はAsnまたはProを表す)
式(IV):Val-Val-Ala-Ala-Ile-X6-Ser-Lys-Tyr-Phe-Ala-Ala-Gln-Tyr-Ala(式(IV)中、X6はAsnまたはThrを表す)
式(V):His-Thr-Phe-Thr-Val-Asn-Val-Lys-Ala-Thr-Ser-Asn-X7-Asn-X8-Lys-Ser-Ala Thr-Leu-Pro-Val (式(V)中、X7はThrまたはValを表し、X8はGlyまたはSerを表す)
式(VI):Val-Thr-Val-Pro-Asn-Val-Ala-Glu-Pro-Thr-Val-X9-Ser-Val-Ser-Lys (式(VI)中、X9はAlaまたはProを表す) - 前記式(I)~(VI)で示されるアミノ酸配列において、1~10個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなるペプチドモチーフの少なくとも1種を含み、かつウロモジュリン(Umod)蛋白質に対して結合活性を有するラクトバチルス属の乳酸菌の表層蛋白質を含有する、請求項1に記載の腸管における物質取り込み促進剤。
- 前記表層蛋白質が、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)、ラクトバチルス・ヘルベティカス(Lactobacillus helveticus)、ラクトバチルス・クリスパタス(Lactobacillus crispatus)、ラクトバチルス・アミロボラス(Lactobacillus amylovorus)、またはラクトバチルス・ガリナルム(Lactobacillus gallinarum)由来のS-layer proteinである、請求項1または2に記載の腸管における物質取り込み促進剤。
- 前記表層蛋白質がラクトバチルス・アシドフィルス由来のSlpA蛋白質である、請求項1~3のいずれかに記載の腸管における物質取り込み促進剤。
- 前記ラクトバチルス・アシドフィルス由来のSlpA蛋白質が以下の(a)~(c)のいずれかの蛋白質である、請求項4に記載の腸管における物質取り込み促進剤。
(a) 配列番号7に示すアミノ酸配列からなる蛋白質
(b) 配列番号7に示すアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる蛋白質
(c) 配列番号7に示すアミノ酸配列と90%以上の配列同一性を有する蛋白質 - 請求項1~5のいずれかに記載の腸管における物質取り込み促進剤と腸管取り込み対象物質との複合体。
- 前記腸管取り込み対象物質が食品成分である、請求項6に記載の複合体。
- 前記食品成分が乳酸菌である、請求項7に記載の複合体。
- 前記腸管取り込み対象物質が医薬品成分である、請求項6に記載の複合体。
- 前記医薬品成分が粘膜ワクチン抗原である、請求項9に記載の複合体。
- 請求項6~10のいずれかに記載の複合体を含む組成物。
- 飲食品、医薬品または動物用飼料である、請求項11に記載の組成物。
- 被検乳酸菌の菌体表層における、下記式(I)~(VI)で示されるアミノ酸配列からなるペプチドモチーフの少なくとも1種を含む蛋白質の発現量を測定することを含む、腸管内移行能が高い乳酸菌のスクリーニング方法。
式(I):Asn-Thr-Asn-Thr-Asn-Ala-Lys-Tyr-Asp-Val-Asp-Val-Thr-Pro-Ser-Val-Ser-Ala-X1-Ala (式(I)中、X1はValまたはIleを表す)
式(II):Gly-X2-Leu-Thr-Gly-X3-Ile-Ser-Ala-Ser-Tyr-Asn-Gly-Lys-X4-Tyr-Thr-Ala Asn-Leu (式(II)中、X2はAsnまたはSerを表し、X3はThrまたはSerを表し、X4はThrまたはSerを表す)
式(III):Tyr-Thr-Val-Thr-Val-X5-Asp-Val-Ser-Phe-Asn-Phe-Gly-Ser-Glu-Asn-Ala- Gly-Lys (式(III)中、X5はAsnまたはProを表す)
式(IV):Val-Val-Ala-Ala-Ile-X6-Ser-Lys-Tyr-Phe-Ala-Ala-Gln-Tyr-Ala(式(IV)中、X6はAsnまたはThrを表す)
式(V):His-Thr-Phe-Thr-Val-Asn-Val-Lys-Ala-Thr-Ser-Asn-X7-Asn-X8-Lys-Ser-Ala Thr-Leu-Pro-Val (式(V)中、X7はThrまたはValを表し、X8はGlyまたはSerを表す)
式(VI):Val-Thr-Val-Pro-Asn-Val-Ala-Glu-Pro-Thr-Val-X9-Ser-Val-Ser-Lys (式(VI)中、X9はAlaまたはProを表す)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016523447A JP6376417B2 (ja) | 2014-05-29 | 2015-05-21 | 腸管における物質取り込み促進剤 |
US15/313,872 US20170202908A1 (en) | 2014-05-29 | 2015-05-21 | Agent for promoting substance incorporation in intestinal tract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-111681 | 2014-05-29 | ||
JP2014111681 | 2014-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015182470A1 true WO2015182470A1 (ja) | 2015-12-03 |
Family
ID=54698806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/064573 WO2015182470A1 (ja) | 2014-05-29 | 2015-05-21 | 腸管における物質取り込み促進剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20170202908A1 (ja) |
JP (1) | JP6376417B2 (ja) |
WO (1) | WO2015182470A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106282178A (zh) * | 2016-09-05 | 2017-01-04 | 南京农业大学 | 重组嗜酸乳杆菌s层蛋白在大肠杆菌中的高效表达及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7497126B2 (ja) * | 2018-11-29 | 2024-06-10 | 雪印メグミルク株式会社 | 抗菌ペプチド産生促進用組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051631A1 (en) * | 1998-04-03 | 1999-10-14 | Timo Korhonen | A protein region responsible of binding to epithelial cell types and a dna sequence encoding said region |
JP2005528085A (ja) * | 2001-12-28 | 2005-09-22 | ネーデルランドセ・オルガニザテイエ・フール・テゲパスト−ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー | 修飾された細菌表層タンパク質 |
WO2006073145A1 (ja) * | 2005-01-04 | 2006-07-13 | Calpis Co., Ltd | 抗アレルギー効果を有する乳酸菌の製造法 |
WO2014167995A1 (ja) * | 2013-04-11 | 2014-10-16 | カルピス株式会社 | 免疫調節作用を有する乳酸菌のスクリーニング方法 |
-
2015
- 2015-05-21 WO PCT/JP2015/064573 patent/WO2015182470A1/ja active Application Filing
- 2015-05-21 JP JP2016523447A patent/JP6376417B2/ja not_active Expired - Fee Related
- 2015-05-21 US US15/313,872 patent/US20170202908A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051631A1 (en) * | 1998-04-03 | 1999-10-14 | Timo Korhonen | A protein region responsible of binding to epithelial cell types and a dna sequence encoding said region |
JP2005528085A (ja) * | 2001-12-28 | 2005-09-22 | ネーデルランドセ・オルガニザテイエ・フール・テゲパスト−ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー | 修飾された細菌表層タンパク質 |
WO2006073145A1 (ja) * | 2005-01-04 | 2006-07-13 | Calpis Co., Ltd | 抗アレルギー効果を有する乳酸菌の製造法 |
WO2014167995A1 (ja) * | 2013-04-11 | 2014-10-16 | カルピス株式会社 | 免疫調節作用を有する乳酸菌のスクリーニング方法 |
Non-Patent Citations (5)
Title |
---|
AATTOURI, N. ET AL.: "Oral ingestion of lactic- acid bacteria by rats increases lymphocyte proliferation and interferon-y production", BRITISH JOURNAL OF NUTRITION, vol. 87, no. 04, 2002, pages 367 - 373, XP055242259, ISSN: 0007-1145 * |
HOLLMANN, A. ET AL.: "S-layer proteins from lactobacilli as vaccine delivery systems", INTERNATIONAL JOURNAL OF MICROBIOLOGY RESEARCH, vol. 2, no. 2, 2010, pages 30 - 43, XP055242260, ISSN: 0975-5276 * |
HYNONEN, U. ET AL.: "Lactobacillus surface layer proteins: structure, function and applications", APPL MICROBIOL BIOTECHNOL, vol. 97, no. 12, 2013, pages 5225 - 5243, XP035328899, ISSN: 0175-7598 * |
MOEINI, H. ET AL.: "Lactobacillus acidophilus as a live vehicle for oral immunization against chicken anemia virus", APPL MICROBIOL BIOTECHNOL, vol. 90, no. 1, 2011, pages 77 - 88, XP019889709, ISSN: 0175-7598 * |
XUEYAN, C. ET AL.: "Characterization of Surface Layer Proteins in Lactobacillus crispatus Isolate ZJ001", J. MICROBIOL. BIOTECHNOL., vol. 19, no. 10, 2009, pages 1176 - 1183, XP055242257 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106282178A (zh) * | 2016-09-05 | 2017-01-04 | 南京农业大学 | 重组嗜酸乳杆菌s层蛋白在大肠杆菌中的高效表达及其应用 |
CN106282178B (zh) * | 2016-09-05 | 2019-06-04 | 南京农业大学 | 重组嗜酸乳杆菌s层蛋白在大肠杆菌中的高效表达及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2015182470A1 (ja) | 2017-06-01 |
US20170202908A1 (en) | 2017-07-20 |
JP6376417B2 (ja) | 2018-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Le Maréchal et al. | Surface proteins of Propionibacterium freudenreichii are involved in its anti-inflammatory properties | |
RU2294366C2 (ru) | Трансформированные молочно-кислые бактерии, снижающие склонность к проявлению аллергических реакций, и их применение | |
Kajikawa et al. | Dissimilar properties of two recombinant Lactobacillus acidophilus strains displaying Salmonella FliC with different anchoring motifs | |
AU2005316041B2 (en) | Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound | |
AU2002256639B2 (en) | Lactic acid bacteria as agents for treating and preventing allergy | |
AU2002220561A1 (en) | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions | |
Ma et al. | Screening and identification of a chicken dendritic cell binding peptide by using a phage display library | |
Xu et al. | Rapid detection of Campylobacter jejuni using fluorescent microspheres as label for immunochromatographic strip test | |
Oh et al. | Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route | |
JP6376417B2 (ja) | 腸管における物質取り込み促進剤 | |
Niu et al. | Immune evaluation of recombinant Lactobacillus plantarum with surface display of HA1-DCpep in mice | |
US20230068615A1 (en) | Microbiota-Derived Proteins Inducing Il-10 Release From Human Cells And Uses Thereof | |
EP4135733A2 (en) | Engineered probiotics for treatment and immunity against viruses | |
TW201732041A (zh) | 經修飾之初乳蛋白質及其應用 | |
Liu et al. | Identification of the Lactobacillus SLP domain that binds gastric mucin | |
Kim et al. | Identification of a peptide enhancing mucosal and systemic immune responses against EGFP after oral administration in mice | |
Panwar et al. | Insights into involvement of S-layer proteins of probiotic Lactobacilli in relation to gut health | |
Su et al. | Construction of Lactobacillus rhamnosus GG particles surface display system | |
Niu et al. | A novel bacterium-like particles platform displaying antigens by new anchoring proteins induces efficacious immune responses | |
CN107417773B (zh) | 黏合细胞壁之胜肽 | |
US20150196634A1 (en) | Cultured myeloid dendritic cells isolated from peyers patches and uses thereof | |
Chalet | Surface proteins of Propionibacterium freudenreichii are involved in its anti-inflammatory properties | |
Le Maréchal et al. | are involved in its anti-inflammatory properties | |
Stuknyte | BIOACTIVES IN MILK-DERIVED PRODUCTS: BACTERIAL PRODUCTION OF IMMUNOMODULATORY CASEIN HYDROLYSATES AND TOOLS FOR IDENTIFICATION OF IMMUNOGENIC BACTERIAL PROTEIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15799905 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15313872 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016523447 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15799905 Country of ref document: EP Kind code of ref document: A1 |